国产农村熟妇videos,激情综合网五,久久久GOGO无码啪啪艺术

您好，歡迎來(lái)到拜力生物網(wǎng)站！請(qǐng)登錄注冊(cè)

我的訂單 | 聯(lián)系我們 | 在線客服QQ：3012681483 | 客服電話：400-968-7988 | 工作時(shí)間：08:30-17:30

主營(yíng)產(chǎn)品： ELISA試劑盒、抗體、補(bǔ)體血清、兔補(bǔ)體、干擾素、小鼠測(cè)溫儀、進(jìn)口試劑、Quidel代理、Swant代理、PBL Assay Science代理

網(wǎng)站首頁(yè) 產(chǎn)品中心代理品牌新聞資訊資源中心關(guān)于我們

所在位置：首頁(yè) > 產(chǎn)品中心 > Antibodies > Antibodies產(chǎn)品

訂購(gòu)信息

上海拜力生物科技公司

Tel:400-968-7988 021-33779008

Anti-BRCA1 (Ab-1524) Antibody

品牌：Antibodies

貨號(hào)：

規(guī)格：50μl

貨期：

應(yīng)用：

咨詢客服

立即購(gòu)買加入購(gòu)物車

Anti-BRCA1 (Ab-1524) Antibody

商品詳情參考文獻(xiàn) 相關(guān)資料

Overview

Name:	Anti-BRCA1 (Ab-1524) Antibody See all BRCA1 primary antibodies
Description:	Rabbit polyclonal antibody to BRCA1 (Ab-1524)
Specificity:	The antibody detects endogenous level of total BRCA1 protein.
Applications:	WB, IF
Reactivity:	Human
Immunogen:	Peptide sequence around aa.1522~1526 (Y-P-S-Q-E) derived from Human BRCA1.
Host:	Rabbit
Clonality:	Polyclonal
Conjugate:	Unconjugated
Purification:	Antibodies were produced by immunizing rabbits with synthetic peptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific peptide.
Concentration:	1.0mg / ml
Formulation:	Supplied at 1.0mg / mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Storage:	Store at -20°C for long term preservation (recommended). Store at 4°C for short term use.

Target

Function:	E3 ubiquitin-protein ligase that specifically mediates the formation of 'Lys-6'-linked polyubiquitin chains and plays a central role in DNA repair by facilitating cellular responses to DNA damage. It is unclear whether it also mediates the formation of other types of polyubiquitin chains. The E3 ubiquitin-protein ligase activity is required for its tumor suppressor function. The BRCA1-BARD1 heterodimer coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. Regulates centrosomal microtubule nucleation. Required for normal cell cycle progression from G2 to mitosis. Required for appropriate cell cycle arrests after ionizing irradiation in both the S-phase and the G2 phase of the cell cycle. Involved in transcriptional regulation of P21 in response to DNA damage. Required for FANCD2 targeting to sites of DNA damage. May function as a transcriptional regulator. Inhibits lipid synthesis by binding to inactive phosphorylated ACACA and preventing its dephosphorylation. Contributes to homologous recombination repair (HRR) via its direct interaction with PALB2, fine-tunes recombinational repair partly through its modulatory role in the PALB2-dependent loading of BRCA2-RAD51 repair machinery at DNA breaks. Component of the BRCA1-RBBP8 complex which regulates CHEK1 activation and controls cell cycle G2/M checkpoints on DNA damage via BRCA1-mediated ubiquitination of RBBP8. Acts as a transcriptional activator (PubMed:20160719).
Tissue Specificity:	Isoform 1 and isoform 3 are widely expressed. Isoform 3 is reduced or absent in several breast and ovarian cancer cell lines.
Involvement in Disease:	Breast cancer: A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case. Breast-ovarian cancer, familial, 1: A condition associated with familial predisposition to cancer of the breast and ovaries. Characteristic features in affected families are an early age of onset of breast cancer (often before age 50), increased chance of bilateral cancers (cancer that develop in both breasts, or both ovaries, independently), frequent occurrence of breast cancer among men, increased incidence of tumors of other specific organs, such as the prostate. Ovarian cancer: The term ovarian cancer defines malignancies originating from ovarian tissue. Although many histologic types of ovarian tumors have been described, epithelial ovarian carcinoma is the most common form. Ovarian cancers are often asymptomatic and the recognized signs and symptoms, even of late-stage disease, are vague. Consequently, most patients are diagnosed with advanced disease. Pancreatic cancer 4: A malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue.
Post-Translational Modification:	Phosphorylation at Ser-308 by AURKA is required for normal cell cycle progression from G2 to mitosis. Phosphorylated in response to IR, UV, and various stimuli that cause checkpoint activation, probably by ATM or ATR. Phosphorylation at Ser-988 by CHEK2 regulates mitotic spindle assembly.
Cellular Location:	Nucleus. Chromosome. Cytoplasm. Localizes at sites of DNA damage at double-strand breaks (DSBs); recruitment to DNA damage sites is mediated by FAM175A and the BRCA1-A complex (PubMed:26778126). Translocated to the cytoplasm during UV-induced apoptosis (PubMed:20160719).
Database Links:	Entrez Gene: 672?Human Omim: 113705?Human SwissProt: P38398?Human Unigene: 194143?Human
Synonyms:	BRCA 1 Antibody BRCA1 Antibody BRCA1 DNA repair associated Antibody BRCA1/BRCA2 containing complex subunit 1 Antibody BRCA1/BRCA2-containing complex, subunit 1 Antibody BRCA1_HUMAN Antibody BRCAI Antibody BRCC 1 Antibody BRCC1 Antibody Breast and ovarian cancer susceptibility protein 1 Antibody Breast Cancer 1 Antibody Breast Cancer 1 Early Onset Antibody Breast cancer type 1 susceptibility protein Antibody BROVCA1 Antibody FANCS Antibody IRIS Antibody PNCA4 Antibody PPP1R53 Antibody Protein phosphatase 1 regulatory subunit 53 Antibody PSCP Antibody RING finger protein 53 Antibody RNF53 Antibody
Information:	Target information shown above is from the UniProt Consortium.